Bioline Rx Ltd BLRX

NAS: BLRX | ISIN: US09071M2052 30/04/2025

3,470 USD (+7,76%)

(+7,76%) 30/04/2025

Grafiek Bioline Rx Ltd

Grafiek Bioline Rx Ltd

1 dag1d 7,76%
1 week1w 15,59%
1 maand1m 18,84%
3 maanden3m 2,36%
6 maanden6m 714,36%
1 jaar1j 416,29%
5 jaar5j 110,30%

Bioline Rx Ltd in het nieuws

Toon enkel gratis nieuws

31 maart 2025 · BioLineRx Reports 2024 Financial Results and Provides Corporate Update · Persbericht

24 maart 2025 · BioLineRx to Report 2024 Annual Results on March 31, 2025 · Persbericht

15 augustus 2024 · BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates · Persbericht

8 augustus 2024 · BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 · Persbericht

30 mei 2024 · BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) · Persbericht

28 mei 2024 · BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates · Persbericht

24 mei 2024 · BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting · Persbericht

22 mei 2024 · BioLineRx to Report First Quarter 2024 Results on May 28, 2024 · Persbericht

17 mei 2024 · BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification · Persbericht

6 mei 2024 · BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 · Persbericht

Profiel Bioline Rx Ltd

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

CEO: Philip Serlin

Werknemers: 58

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe